Multicenter Management of Breast Cancer in Indonesia: Ten Years of Experience

Gondhowiardjo, Soehartati; Soediro, Ratnawati; Jayalie, Vito Filbert; Djoerban, Zubairi; Siregar, Nurjati Chairani; Poetiray, Evert

doi:10.23886/ejki.8.11020.

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To exemplify the benefit of this study in issuing the imbalance of trial-patient rate, the US National Library of Medicine only recorded a single-active trial of TNBC in Indonesia; though Indonesia is placing the fourth in total population (2023 report by the Worldometer, 49.7% is female; approximately ± 135 million individuals) [6,61]. We also estimated that 17.8% of the BC diagnosis in Indonesia is triple-negative on IHC [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. Supported by the GLOBOCAN 2020 country-specific report, at least there was 65,858 total BC cases (in which 11,000 -12,000 of the patients are estimated to be TNBC on testing) [1].…”

Section: Discussionmentioning

confidence: 99%

Intercontinental Comparison of Immunohistochemical Subtypes Among Individuals With Breast Cancer in South-East Asia and South America: A Scoping Systematic Review and Meta-Analysis of Observational Studies

Hermansyah,

Firsty,

Siagian

et al. 2024

World J Oncol

View full text Add to dashboard Cite

Background Breast cancer (BC) remains a significant global concern, particularly among developing countries in South-East Asia (SEA) and South America (SA). The socioeconomic burdens of oncologic care in those countries were often originated from limited accessibility on attainable therapeutic options and reliability on identifying essential information of cancer cells, i.e., immunohistochemical (IHC) subtyping to determine suitable approaches. The triple-negative breast cancer (TNBC) is among the most aggressive category in breast malignancy, therefore, requiring more specific molecular pathway blocking to exhaust the cells. However, large-scale epidemiological investigation on its rate among BC remains unavailable to date. This study aimed to describe the prevalence of TNBC in the SEA and SA continents since it may guide the future direction of oncologic research and trials. Methods This review focuses on observational studies from the SEA and SA continents from the last decade. Each study represents its country or cities, period of observation, population size, and the TNBC-BC rate as the main outcomes. Therefore, we may also limit the reporting bias originated from same-patient data on the specific occasions. The analysis will be derived to SEA-SA comparison, plus SEA/SA-specific session as processed in Comprehensive Meta-Analysis (CMA) version 3.0. The statistical analysis will be performed in random effects model (REM) within 95% confidence interval (CI). Results From 46 studies included in the final analysis with a total enlisted population of 34,346 unique individuals with BC, the TNBC rate was higher in the SEA compared to the SA region (19.3% vs. 15.7%; P < 0.05 in 95% CI), with the highest prevalence observed in Vietnam (22.4%) and Peru (17.8%), if it was restricted on countries with two or more studies. Interestingly, both Laos and Argentina possessed significant differences compared to other countries within their respective continents, with the highest and lowest TNBC rates (P < 0.05). Conclusions The IHC characteristics in SEA differ from those in the SA continent as mainly represented by TNBC prevalence, possibly shaping the course of future trials in the respective region based on IHC expressivity status.

show abstract

Section: Discussionmentioning

confidence: 99%

Intercontinental Comparison of Immunohistochemical Subtypes Among Individuals With Breast Cancer in South-East Asia and South America: A Scoping Systematic Review and Meta-Analysis of Observational Studies

Hermansyah,

Firsty,

Siagian

et al. 2024

World J Oncol

View full text Add to dashboard Cite

show abstract

“…1 Breast cancer patients require personalized multimodality treatment. 2 , 3 However, effective cancer management can be challenging in LMIC, due to limitations in finances, resources, trained human resources, and infrastructure. Radiotherapy is used to reduce the risk of recurrence and mortality rate after breast‐conserving surgery and adjuvant endocrine therapy.…”

Section: Introductionmentioning

confidence: 99%

“…4 In Indonesia, radiotherapy is performed for 53.7% of all breast cancer patients. 3 Good clinical practice for radiotherapy dictates that complete treatment doses should be administered without interruption or prolongation of overall treatment time (OTT). Incompletion and prolongation OTT of radiotherapy results in negative clinical outcomes including increases the risk of local recurrence and inferior overall survival.…”

Section: Introductionmentioning

confidence: 99%

“…In Indonesia, which is classified among the low‐ and middle‐income countries (LMIC), breast cancer is the most common cancer, with a prevalence of 201,143 and a mortality rate of 9.6% in 2020 1 . Breast cancer patients require personalized multimodality treatment 2,3 . However, effective cancer management can be challenging in LMIC, due to limitations in finances, resources, trained human resources, and infrastructure.…”

Section: Introductionmentioning

confidence: 99%

“…Radiotherapy is used to reduce the risk of recurrence and mortality rate after breast‐conserving surgery and adjuvant endocrine therapy 4 . In Indonesia, radiotherapy is performed for 53.7% of all breast cancer patients 3 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations